Assessing the membranous expression of a potential molecular target of the tumor cell seems plausible as the target is located in the cell membrane and is in line with immunohistochemical assessment of other molecular targets, as e.g., HER2 in breast cancer [26]. The gene discussed is ERBB2; the disease is neoplasm.